Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response - PubMed
3 hours ago
- #Melanoma Surgery
- #Neoadjuvant Immunotherapy
- #ctDNA Biomarker
- Neoadjuvant immune checkpoint inhibitors (ICI) improve outcomes in high-risk resectable melanoma, with a personalized surgical approach being feasible.
- Major pathologic response (MPR) rate was 55%, with comparable recurrence rates between index node excision (INE) and total lymph node dissection (TLND) cohorts.
- Circulating tumor DNA (ctDNA) levels correlated with clinical outcomes, showing undetectable ctDNA in most MPR patients and detectable in few postoperatively.
- Adjuvant therapy improved recurrence-free survival for patients without MPR, highlighting ctDNA's potential as a biomarker to guide management.